Research programme: infectious disease vaccines - AltraVax

Drug Profile

Research programme: infectious disease vaccines - AltraVax

Alternative Names: Maxy-201

Latest Information Update: 14 Jan 2013

Price : $50

At a glance

  • Originator Maxygen; The Scripps Research Institute
  • Developer AltraVax
  • Class AIDS vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Dengue; Hepatitis B; HIV-1 infections
  • Research Influenza virus infections

Most Recent Events

  • 08 Jan 2013 Altravax receives SBIR grants from the National Institute of Allergy and Infectious Diseases for vaccine development in Dengue (prevention) and Hepatitis B
  • 05 Dec 2012 Preclinical development in HIV-1 infections is ongoing in USA
  • 01 Dec 2012 Preclinical trials in Dengue in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top